AtriCure (NASDAQ:ATRC) Given New $52.00 Price Target at Citizens Jmp

AtriCure (NASDAQ:ATRC) had its price target trimmed by Citizens Jmp from $60.00 to $52.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a market outperform rating on the medical device company’s stock.

Several other research firms also recently commented on ATRC. Weiss Ratings reiterated a “sell (d-)” rating on shares of AtriCure in a research note on Wednesday, January 21st. BTIG Research restated a “buy” rating and issued a $54.00 target price on shares of AtriCure in a research note on Wednesday. Needham & Company LLC reaffirmed a “buy” rating and set a $45.00 price target on shares of AtriCure in a research report on Thursday, February 12th. Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 6th. Finally, Canaccord Genuity Group raised their price objective on AtriCure from $53.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, AtriCure has an average rating of “Moderate Buy” and an average target price of $48.43.

AtriCure Price Performance

Shares of NASDAQ ATRC opened at $32.26 on Wednesday. AtriCure has a fifty-two week low of $28.29 and a fifty-two week high of $43.18. The company has a market cap of $1.60 billion, a PE ratio of -134.42 and a beta of 1.41. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.85 and a current ratio of 3.87. The business has a 50-day simple moving average of $38.59 and a two-hundred day simple moving average of $36.77.

AtriCure (NASDAQ:ATRC) last announced its quarterly earnings data on Tuesday, February 17th. The medical device company reported $0.06 EPS for the quarter, beating the consensus estimate of ($0.04) by $0.10. The firm had revenue of $140.50 million during the quarter, compared to analyst estimates of $140.50 million. AtriCure had a negative net margin of 2.14% and a negative return on equity of 1.17%. AtriCure’s revenue was up 13.1% on a year-over-year basis. During the same period last year, the firm posted ($0.33) EPS. As a group, equities analysts expect that AtriCure will post -0.6 EPS for the current fiscal year.

Insider Activity

In other AtriCure news, Director Sven Wehrwein sold 5,033 shares of the business’s stock in a transaction that occurred on Monday, November 24th. The stock was sold at an average price of $37.32, for a total value of $187,831.56. Following the completion of the transaction, the director directly owned 34,374 shares of the company’s stock, valued at approximately $1,282,837.68. The trade was a 12.77% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Maggie Yuen sold 3,000 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $35.72, for a total value of $107,160.00. Following the completion of the sale, the director owned 11,371 shares in the company, valued at approximately $406,172.12. This represents a 20.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 18,166 shares of company stock valued at $676,378 in the last quarter. 3.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On AtriCure

Several institutional investors have recently made changes to their positions in ATRC. Ameritas Investment Partners Inc. boosted its holdings in AtriCure by 6.7% during the second quarter. Ameritas Investment Partners Inc. now owns 4,941 shares of the medical device company’s stock worth $162,000 after buying an additional 312 shares in the last quarter. PNC Financial Services Group Inc. boosted its stake in shares of AtriCure by 6.5% during the 3rd quarter. PNC Financial Services Group Inc. now owns 6,188 shares of the medical device company’s stock worth $218,000 after acquiring an additional 380 shares in the last quarter. Teacher Retirement System of Texas boosted its stake in shares of AtriCure by 5.4% during the 2nd quarter. Teacher Retirement System of Texas now owns 7,512 shares of the medical device company’s stock worth $246,000 after acquiring an additional 385 shares in the last quarter. Smartleaf Asset Management LLC grew its position in shares of AtriCure by 59.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after acquiring an additional 429 shares during the period. Finally, Scotia Capital Inc. increased its stake in shares of AtriCure by 1.2% in the 3rd quarter. Scotia Capital Inc. now owns 37,677 shares of the medical device company’s stock valued at $1,328,000 after purchasing an additional 457 shares in the last quarter. 99.11% of the stock is owned by hedge funds and other institutional investors.

Key AtriCure News

Here are the key news stories impacting AtriCure this week:

• Positive Sentiment: AtriCure reported Q4 2025 results that beat expectations: $0.06 EPS (vs. estimates for a loss) and $140.5M revenue, +13% year-over-year, and management signaled strong execution and forward momentum — a key fundamental reason for upside interest. AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
• Positive Sentiment: BTIG and other analysts reiterated Buy ratings and maintained ~ $54 price targets, citing sustained outperformance and manageable competition — analyst support can underpin shares going forward. AtriCure: Sustained Outperformance…54 Target
• Neutral Sentiment: Multiple earnings call transcripts and recaps are available (detailed commentary from management and analysts), which investors should read for guidance detail and margin/volume drivers. Q4 2025 Earnings Call Highlights
• Neutral Sentiment: Trading volume is well above average on the earnings day, indicating active repositioning; short-interest data reported appears anomalous and should be treated with caution. ATRC Tops Q4 Earnings
• Negative Sentiment: Citizens JMP cut its price target from $60 to $52 (still a market outperform), a modest downward revision that may temper some upside expectations and contributed to selling pressure. Benzinga: Price Target Change
• Negative Sentiment: Coverage noted rising competition in the Afib device space — a longer‑term risk that could pressure margins or market share if competitors gain traction. AtriCure posts Q4 beats on 13% growth, analysts label it ‘undervalued’ despite rising competition

AtriCure Company Profile

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.